Sarah E. Slater

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Spontaneous regression of eruptive melanocytic naevi on cessation of a BRAF inhibitor.

Spontaneous regression of eruptive melanocytic naevi on cessation of a BRAF inhibitor.

Journal: Clinical and experimental dermatology

Published: April 19, 2026

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation.

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation.

Journal: British journal of cancer

Published: October 01, 2025

A Case of Strongyloidiasis Mimicking a Drug Hypersensitivity Reaction to Imatinib.

A Case of Strongyloidiasis Mimicking a Drug Hypersensitivity Reaction to Imatinib.

Journal: Journal of investigational allergology & clinical immunology

Published: April 25, 2025

Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer.

Fluoropyrimidine Chemotherapy and the Risk of Death and Cardiovascular Events in Patients With Gastrointestinal Cancer.

Journal: JACC. CardioOncology

Published: October 22, 2024

Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.

Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.

Journal: Expert review of gastroenterology & hepatology

Published: October 22, 2024

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

Journal: The Lancet. Oncology

Published: May 08, 2024

Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies.

Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies.

Journal: BMJ oncology

Published: January 09, 2024

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE.

Journal: ESMO open

Published: December 20, 2023

Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator.

Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator.

Journal: ESC heart failure

Published: December 20, 2023

Treating the treatment: chemotherapy-induced multi-organ toxicity.

Treating the treatment: chemotherapy-induced multi-organ toxicity.

Journal: BMJ case reports

Published: March 16, 2021

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma.

Journal: BMC cancer

Published: October 28, 2020

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.

Journal: Nature communications

Published: July 06, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026